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Characterization 
of Mycobacterium 
orygis
To the Editor: We thank Gey 
van Pittius and colleagues for their 
addition to the markers that identify 
Mycobacterium orygis as a distinct 
subspecies in the M. tuberculosis 
complex (1). Its isolation from a wild 
buffalo broadens the host range of 
M. orygis. Gey van Pittius and col-
leagues raise 3 issues: the utility of the 
gyrBoryx single-nucleotide polymor-
phism (SNP) being equally specific 
as the reported SNP in Rv204238, the 
presence of genomic regions RD701 
and RD702 in M. orygis, and the ad-
dition of the sequence type (ST) 701 
spoligotype to M. orygis–specific 
spoligotypes.
We agree that use of the gyrBoryx 
mutation is more practical for routine 
daily use because this gene helps iden-
tify several subspecies of the M. tuber-
culosis complex. However, use of the 
partial Rv2042 sequencing is similarly 
practical because it can be combined 
with sequencing of the adjacent pncA 
gene, which enables identification of 
several M. tuberculosis complex spe-
cies and some subspecies (i.e., M. 
orygis, M. bovis, M. canettii) (2), to 
identify the CAS genotype of M. tu-
berculosis (J. van Ingen, unpub. data) 
and, to some degree, assess suscepti-
bility to pyrazinamide (3).
With the added data, we can 
conclude that M. orygis is an M. tu-
berculosis complex subspecies de-
fined by the presence of genomic re-
gions RD1, RD2, RD4, RD5a, RD6, 
RD13–RD16, RD701, and RD702, by 
the C-to-G SNP in mmpL6551, and by 
the deletion of regions RD3, RD5b, 
RD7-RD12, RDoryx_1, RDoryx_4, 
and RDoryx_wag22. Subspecies-
specific SNPs are present in gyrB and 
Rv2042. Spoligotypes ST587, ST701, 
and closely related types are charac-
teristic of M. orygis, and this subspe-
cies yields 17–20 copies of insertion 
sequence 6110 and a distinct 24-locus 
variable number tandem repeats pat-
tern (4,5). Given the rapid progress in 
genome sequencing, additional mark-
ers specific for the different subspe-
cies will further enrich this panel of 
differences.
Jakko van Ingen,  
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Author	 affiliations:	 Radboud	 University	 Ni-
jmegen	Medical	Center,	Nijmegen,	the	Neth-
erlands	(J.	van	Ingen,	D.	van	Soolingen);	In-
stitut	Pasteur,	Paris,	France	(R.	Brosch);	and	
National	 Institute	 for	Public	Health	and	 the	
Environment	(RIVM),	Bilthoven,	the	Nether-
lands	(D.	van	Soolingen)	
DOI:	http://dx.doi.org/10.3201/eid1903.121005
References 
  1.  Gey van Pittius NC, van Helden PD, 
Warren RM. Characterization of My-
cobacterium orygis. Emerg Infect 
Dis. 2012;18:1708–9. http://dx.doi.
org/10.3201/eid1810.120569
  2.  Huard RC, Fabre M, de Haas P, Oliveira 
Lazzarini LC, van Soolingen D, Cousins 
D, et al. Novel genetic polymorphisms 
that further delineate the phylogeny of 
the Mycobacterium tuberculosis complex. 
J Bacteriol. 2006;188:4271–87. http://
dx.doi.org/10.1128/JB.01783-05
  3.  Simons SO, van Ingen J, van der Laan T, 
Mulder A, Dekhuijzen PN, Boeree MJ, et 
al. Validation of pncA gene sequencing 
in combination with the MGIT method 
to test susceptibility of Mycobacterium 
tuberculosis to pyrazinamide. J Clin Mi-
crobiol. 2012;50:428–34. http://dx.doi.
org/10.1128/JCM.05435-11
	 Emerging	Infectious	Diseases	•	www.cdc.gov/eid	•	Vol.	19,	No.	3,	March	2013	 521
LETTERS
  4.  van Ingen J, Rahim Z, Mulder A, Boeree 
MJ, Simeone R, Brosch R, et al. Charac-
terization of Mycobacterium orygis as M. 
tuberculosis complex subspecies. Emerg 
Infect Dis. 2012;18:653–5. http://dx.doi.
org/10.3201/eid1804.110888
  5.  Gey van Pittius NC, Perrett KD, Mi-
chel AL, Keet DF, Hlokwe T, Streicher 
EM, et al. Infection of African buffalo 
(Syncerus caffer) by oryx bacillus, a 
rare member of the antelope clade of 
the Mycobacterium tuberculosis com-
plex. J Wild Dis. 2012;48:849–57. doi: 
10.7589/2010-07-178.
Address for correspondence: Jakko van Ingen, 
Medical Microbiology, Radboud University 
Nijmegen Medical Center, PO Box 9101, 
Nijmegen 6500 HB, the Netherlands; email: 
vaningen.jakko@gmail.com
Mycobacterium  
tuberculosis  
Beijing Type  
Mutation Frequency
To the Editor: A striking finding 
in the study by de Steenwinkel et al. 
(1) is the high frequency of mutation 
to rifampin resistance by 2 Mycobac-
terium tuberculosis Beijing strains, 
which might play a role in the associ-
ation between the Beijing strains and 
multidrug-resistant tuberculosis. Ear-
lier reported frequency of mutation to 
rifampin resistance by M. tuberculo-
sis has been 10−8 CFU (2,3), includ-
ing the Beijing genotype (3,4). Of 
note, the Beijing 2002–1585 strain, 
for which frequency of mutation to 
rifampin resistance is 10-3 CFU (1 
mutant/1,000 CFU), showed a mod-
erate frequency of 10−8 CFU in anoth-
er study (4). We think that a mutation 
frequency increase of 100,000× is re-
markably high. In contrast, rifampin-
resistant mutants of the Beijing 1585 
strain did not emerge in low-density 
cultures (5 × 105 CFU/mL) used for 
time-kill kinetics experiments, al-
though frequency of mutation to ri-
fampin resistance was determined to 
be 10-3 CFU.
Mutation frequency is deter-
mined by fluctuation assays. To ex-
clude preexisting mutants, which 
would bias the mutation frequency by 
so-called jackpots, a series of low-in-
oculum cultures is typically used (5). 
However, for unknown reasons, de 
Steenwinkel et al. used only 1 high-
density culture of 1010 CFU of each 
strain to determine mutation frequen-
cy. This strategy is not recommended 
because mutations can occur early 
or late, resulting in substantial mu-
tation frequency fluctuation between 
test episodes. A strain with known 
mutation rates should preferably be 
included to rule out possible techni-
cal errors.
We propose the following expla-
nations for the remarkable results: 1) 
the rifampin concentration for select-
ing mutants might have been too low, 
enabling growth of some colonies of 
drug-susceptible bacteria; 2) rifampin 
mutants arose early or preexisted 
in the cultivation of Beijing strains 
1585 and 1607, producing jackpots; 
or 3) the 2 Beijing isolates might 
contain rifampin-resistant subpopula-
tions (heteroresistance). The capacity 
of the Beijing strain to develop and, 
especially, transmit multidrug-resis-
tant tuberculosis remains to be fur-
ther analyzed.
Jim Werngren
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In Response: We explain the 
differing frequencies of mutation 
to rifampin resistance mentioned 
by Werngren (1). First, the strains 
of Mycobacterium tuberculosis that 
we tested differed from those previ-
ously tested (2). Second, we used 
different rifampin concentrations in 
subculture plates. For Beijing strain 
2002–1585, Bergval et al. (3) found 
a mutation frequency of 4–24 × 10−8 
at a subculture concentration of 8 
mg/L, whereas we found a mutation 
frequency of 3–4 × 10−3 at a subcul-
ture concentration of 1 mg/L and a 
lower mutation frequency at 2 mg/L. 
Thus, the concentration of drugs in 
subculture plates is crucial to mutation 
frequency assays. Absent a subculture 
concentration standard, we applied ri-
fampin at 1 mg/L (4) because bacteria 
growing at this concentration are con-
sidered resistant to rifampin. Our mu-
tation frequency and time-kill kinet-
ics assay results are not contradictory 
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